SSA
MBX

Schonfeld Strategic Advisors’s MBX Biosciences MBX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7M Sell
123,814
-43,311
-26% -$1.47M 0.03% 587
2025
Q4 		$5.27M Sell
167,125
-115,552
-41% -$2.8M 0.02% 525
2025
Q3 		$4.95M Sell
282,677
-348,736
-55% -$4.66M 0.03% 595
2025
Q2 		$7.2M Buy
631,413
+430,771
+215% +$4.39M 0.05% 443
2025
Q1 		$1.48M Buy
200,642
+129,142
+181% +$1.37M 0.01% 1113
2024
Q4 		$1.32M Buy
+71,500
New +$1.52M 0.01% 1006

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Schonfeld Strategic Advisors's MBX Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its MBX Biosciences (MBX) stake by 26% in Q1 2026, selling an estimated $1.47M and leaving 123,814 shares worth $3.7M. The position accounts for 0.03% of the portfolio, ranked #587.

Schonfeld Strategic Advisors first reported a position in MBX in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.2M in Q2 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Schonfeld Strategic Advisors held 123,814 shares of MBX Biosciences worth $3.7M as of Q1 2026.
  • Schonfeld Strategic Advisors sold 43,311 MBX Biosciences shares in Q1 2026, an estimated $1.47M.
  • MBX Biosciences made up 0.03% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #587 holding.
  • Schonfeld Strategic Advisors first reported a position in MBX Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Schonfeld Strategic Advisors's MBX Biosciences position peaked at $7.2M in Q2 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.